|
gptkbp:instance_of
|
gptkb:immunotherapy
|
|
gptkbp:administered_by
|
oral tablet
intravenous injection
|
|
gptkbp:affects
|
viral load
CD4 cell count
|
|
gptkbp:approves
|
gptkb:1987
gptkb:FDA
|
|
gptkbp:associated_with
|
prolonged survival in HIV patients
reduced transmission of HIV
|
|
gptkbp:available_on
|
generic drug
|
|
gptkbp:brand
|
gptkb:Retrovir
|
|
gptkbp:chemical_formula
|
C10 H13 N5 O4 S
|
|
gptkbp:clinical_trial
|
Phase II
Phase III
Phase I
|
|
gptkbp:community_impact
|
widely used in developing countries
part of global health initiatives
|
|
gptkbp:contraindication
|
severe liver disease
hypersensitivity to zidovudine
|
|
gptkbp:developed_by
|
gptkb:Burroughs_Wellcome
|
|
gptkbp:discovered_by
|
gptkb:1964
|
|
gptkbp:dosage_form
|
gptkb:Sugar
gptkb:capsule
gptkb:liquid
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:historical_significance
|
first drug approved for HIV treatment
pioneered antiretroviral therapy
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
AZT
|
|
gptkbp:influences
|
immune response
|
|
gptkbp:interacts_with
|
gptkb:ribavirin
other antiretrovirals
probenecid
|
|
gptkbp:invention
|
patented
|
|
gptkbp:known_as
|
gptkb:zidovudine
|
|
gptkbp:lifespan
|
1 hour
|
|
gptkbp:marketed_as
|
gptkb:Glaxo_Smith_Kline
|
|
gptkbp:mechanism_of_action
|
inhibits reverse transcriptase
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:part_of
|
HAART therapy
|
|
gptkbp:produced_by
|
synthetic processes
|
|
gptkbp:provides_guidance_on
|
combination therapy
monotherapy
|
|
gptkbp:research_focus
|
combination therapies
drug resistance
HIV/ AIDS treatment
|
|
gptkbp:safety_measures
|
adverse event reporting
post-marketing surveillance
|
|
gptkbp:side_effect
|
gptkb:anemia
fatigue
headache
nausea
|
|
gptkbp:used_for
|
treatment of HIV
|
|
gptkbp:bfsParent
|
gptkb:Baku
gptkb:Azerbaijan
|
|
gptkbp:bfsLayer
|
4
|